Literature DB >> 20213217

The outcome of unintentional pediatric bupropion ingestions: a NPDS database review.

Michael C Beuhler1, Henry A Spiller, Howell C Sasser.   

Abstract

Unintentional bupropion pediatric exposures uncommonly report severe clinical effects such as seizures. We sought to determine the clinical effects and case outcomes for unintentional bupropion ingestions in children age </=6 years. The National Poison Data System was queried for unintentional, acute, single substance bupropion ingestions in children age </=6 years for the time period January 1, 2000 to February 27, 2007 for cases followed to a known outcome. If exposure amount was reported, a mg/kg dose was determined; when weight was absent, it was interpolated from the available data set. An adverse neurological effect (ANE) was defined as seizure (single, multi/discrete, and status) or coma. For analysis, the outcomes of no effect and mild outcome were grouped, and the outcomes of moderate outcome, major outcome, and death were grouped. A subset of case notes were reviewed for accuracy. Seven thousand one hundred eighteen cases met the inclusion criteria, with 1,154 cases excluded because of multiple substances and coding errors, resulting in 5,964 cases. A total of 4,557 cases (76.4%) were managed at or sent to a HCF. The most common clinical effects reported were nausea/vomiting (4.3%), tachycardia (3.9%), agitated/irritable (3.1%), drowsiness/lethargy (2.4%), and seizure (1.4%). There were no deaths. Overall, there was a 3.3% rate of moderate/major outcomes. A mg/kg dose was calculable in 76.1% of cases; the average amount for the no effect/minor cases and moderate/major effect was 13.8 +/- 18.8 and 38.8 +/- 44.0 mg/kg, respectively (p < 0.0001). Average time until development of seizures was 4.2 +/- 3.2 h with a maximum of 14 h. Few children develop toxicity from unintentional reported bupropion ingestions, with about 1.5% of patients developing an ANE.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20213217      PMCID: PMC3550434          DOI: 10.1007/s13181-010-0027-4

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  5 in total

1.  Bupropion exposures: clinical manifestations and medical outcome.

Authors:  Martin G Belson; Todd R Kelley
Journal:  J Emerg Med       Date:  2002-10       Impact factor: 1.484

2.  Intentional bupropion overdoses.

Authors:  Greene Shepherd; Larissa I Velez; Daniel C Keyes
Journal:  J Emerg Med       Date:  2004-08       Impact factor: 1.484

3.  A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor.

Authors:  Stephen M. Stahl; James F. Pradko; Barbara R. Haight; Jack G. Modell; Carol B. Rockett; Susan Learned-Coughlin
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

4.  Unintentional ingestion of bupropion in children.

Authors:  Henry A Spiller; George M Bosse; Michael Beuhler; Ted Gray; S David Baker
Journal:  J Emerg Med       Date:  2008-07-26       Impact factor: 1.484

5.  Bupropion poisoning: a case series.

Authors:  Corrine R Balit; Christa N Lynch; Geoffrey K Isbister
Journal:  Med J Aust       Date:  2003-01-20       Impact factor: 7.738

  5 in total
  3 in total

1.  Pediatric Bupropion Ingestions in Adolescents vs. Younger Children-a Tale of Two Populations.

Authors:  Steve Offerman; Michael Levine; Jasmin Gosen; Stephen H Thomas
Journal:  J Med Toxicol       Date:  2019-11-11

2.  Pediatric Toxidrome Simulation Curriculum: Bupropion Overdose.

Authors:  Emily Hartford; Anita Thomas; Ashley Keilman; Neil Uspal; Kimberly Stone; Jennifer Reid; Rebekah Burns
Journal:  MedEdPORTAL       Date:  2019-10-25

Review 3.  Consensus statements on the clinical understanding and use of bupropion in Hong Kong.

Authors:  Wing-King Lee; Kwok-Leung Au Yeung; Ho-Bun Lam; Chi-Keung Wong; Ting-Chi Wong; Chi-Kin Fu; Shiu-Kow Sham; Ming-Kai Au; Tat-Chung Lam; Daniel Ki-Yan Mak
Journal:  CNS Neurosci Ther       Date:  2021-03       Impact factor: 5.243

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.